Overview

Olinvacimab With Pembrolizumab in Patients With mTNBC

Status:
Not yet recruiting
Trial end date:
2026-08-30
Target enrollment:
Participant gender:
Summary
The objective is to evaluate the efficacy and safety of Olinvacimab in combination with Pembrolizumab in patients with mTNBC.
Phase:
Phase 2
Details
Lead Sponsor:
PharmAbcine
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Pembrolizumab